Lonza Group AG / Key word(s): Miscellaneous Lonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly formed CDMO Business Platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities The model comes into effect today, and is reflected on the updated website Basel, Switzerland, 1 April 2025 – Lonza has announced that its new simplified and streamlined o...
Lonza Group AG / Key word(s): Share Buyback Lonza Completes its Share Buyback Program 01.04.2025 / 07:00 CET/CEST Basel, Switzerland, 1 April 2025 – Lonza today announced the successful completion of its share buyback program of up to CHF 2 billion which was launched on 3 April 2023. Through the program, Lonza repurchased 4,239,731 of its shares on a second trading line on the SIX Swiss Exchange for an average purchase price of CHF 471.7279 per share.The Board of Directors intends to use the capital band to cancel the shares repurchased under the share buyback program. More informa...
A director at Lonza Group AG bought 270 shares at 546.082CHF and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Today’s CMD sets out a clear strategy for the next decade, creating a streamlined & more focused Lonza. The Capsules & Health Ingredients (CHI) business will go, leaving behind a pure-play BioPharma CDMO with 14% sales and 18% EBITDA CAGR 24-29, on our numbers. Our downgrade in Sept was predicated on higher near to mid-term risks to forecasts. With 2025 forecasts now underpinned, cost efficiencies & greater clarity on the shape of the sales growth to 2028, we now believe Lonza is the most attrac...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.